Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRAD3: Sacituzumab tirumotecan concurrent with radiotherapy for unresectable stage III NSCLC
ChiCTR2600135987Phase 2Not yet recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Mar 2027
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC), sponsored by Anhui Provincial Tumor Hospital. Primary endpoint: Incidence of grade 3 or higher treatment-related adverse events during concurrent therapy and within 3 months after completion. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600135987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135987.